Sex: M
Vaccine: COVID19, VARZOS, VARZOS
Symptoms: Herpes zoster, Post herpetic neuralgia, Vaccination failure
Clinical narrative: he now has PHN (post-herpeticneuralgia)/PHN is chronic; he has had it for the past 18 months; Vaccination Failure- developed shingles after being fully vaccinated  [sequelae: PHN]/suspected vaccination failure; Vaccination Failure- developed shingles after being fully vaccinated  [sequelae: PHN]; This serious case was reported by a consumer via call center representative and described the occurrence of vaccination failure in a 75-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis and COVID-19 VACCINE (COVID-19 BOOSTER) for prophylaxis.   Previously administered products included Zostavax (prior injection with shingles live vaccine (Zostavax) at age 65).   On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. In AUG-2021, the patient received COVID-19 BOOSTER. In SEP-2021, 1 year after receiving Shingrix and Shingrix, the patient experienced vaccination failure (Verbatim: Vaccination Failure- developed shingles after being fully vaccinated  [sequelae: PHN]/suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: Vaccination Failure- developed shingles after being fully vaccinated  [sequelae: PHN]). On an unknown date, the patient experienced post herpetic neuralgia (Verbatim: he now has PHN (post-herpeticneuralgia)/PHN is chronic; he has had it for the past 18 months). The patient was treated with antivirals nos (Antiviral (Drug Name Unknown)). The outcome of the vaccination failure was unknown and the outcome of the shingles and post herpetic neuralgia were resolved with sequelae.   The reporter considered the vaccination failure, shingles and post herpetic neuralgia to be unrelated to Shingrix and Shingrix.   The company considered the vaccination failure, shingles and post herpetic neuralgia to be unrelated to Shingrix and Shingrix.   Additional Information: GSK receipt date: 6-Jul-2023 The patient had completed the Shingrix 2-dose series in 2020 and about one year later developed shingles. About one month before his shingles outbreak (in August 2021) he received unspecified Covid-19 booster and felt that the Covid-19 vaccine booster caused him (or made him more susceptible) to developing shingles. The shingles diagnosis was delayed (he was misdiagnosed with diverticulosis in the emergency room (ER) and therefore treatment with anti-viral medications was delayed).  The patient was finally diagnosed with shingles by a neurologist a month after his symptoms began and as a result of the shingles, he now has had post herpetic neuralgia. The post herpetic neuralgia was chronic and has had it for the past 18 months. The patient did not had the exact dates of Shingrix doses but provided pharmacy and doctor of medicine contact information. The patient did remember that the second dose was correctly given within the 2 to 6 month dosing window. The caller did not blame GlaxoSmithKline or Shingrix for his shingles outbreak.  Emergency room visit was required. The patient did not want to share his email address with GlaxoSmithKline. The reporter consented to follow-up. This case was considered as suspected vaccination failure since the details regarding the laboratory confirmation of shingles were unknown at the time of reporting. The reporter considered the shingles to be possibly related to Covid-19 booster and it was unknown if the reporter considered the post herpetic neuralgia to be related to Covid-19 booster.